Researchers based at the Department of Biomedical Engineering, University of Houston, Texas and the Department of Ophthalmology, Duke University Medical Centre, Durham, North Carolina, have… Read More »Maintaining proper RHO:PRPH2 ratios in photoreceptors may provide a potential therapeutic approach for intervention.
Dear EURETINA Members, A very warm welcome to the June 27th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »June 27th, 2024 “EURETINA-Brief”© Issue No. 294
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the completion in the first cohort for a Phase… Read More »Opus Genetics Inc., has announced completion of dowsing in first cohort Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.
A new real-world study, led by Massachusetts General Hospital, Harvard Medical School, Boston, US, have reported a major adverse event on hydroxychloroquine retinopathy, with an… Read More »Hydroxychloroquine dose and duration of use are associated with the risk of hydroxychloroquine retinopathy in a US study.
Researchers based at the MRC Human Genetics Unit, at the University of Edinburgh, and the Western General Hospital (Edinburgh), have reported a new study indicating… Read More »X-linked retinitis pigmentosa (XLRP) due to RPGR variants report new data on actin dynamics.
Dear EURETINA Members, A very warm welcome to the June 10th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »June 10th, 2024 “EURETINA-Brief”© Issue No. 293
A consortium of researchers across Australia, New Zealand, USA, Italy, Portugal, Singapore, Netherlands, Taiwan and Canada, have reported a new study evaluating clinical, electrophysiological and… Read More »Variants in peripherin 2 (PRPH2 gene) shows genetic, functional and clinical observations on 241 IRD patients.
A large real-world prospective study on the long-term effectiveness and safety of faricimab and “Port Delivery System with ranibizumab” (PDS), for nAMD or DME, is… Read More »Real-world data on treatment of AMD/DME patients with faricimab and port delivery system with ranibizumab will run to 2027 (“VOYAGER” ).
Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced the completion of dosing in their second cohort of its Phase 1/2… Read More »Ocugen Inc completes dosing of a Phase 1/2 study for a modifier gene therapy to treat Stargardt disease.
Dear EURETINA Members, A very warm welcome to the May 27th, 2024 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA are delighted to continue… Read More »May 27th, 2024 “EURETINA-Brief”© Issue No. 292
